MET and esophageal adenocarcinoma: Specifically, MET gene amplification and consequent overexpression is an ‘oncogenic driver’ in a subset (∼5%) of gastric and esophageal adenocarcinomas [4], [11]–[14], while MET mutations have been rarely reported in various hereditary and sporadic cancers including gastroesophageal adenocarcinomas (GEC) [15].